Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation, Japan’s leading pharma logistics company, have formed a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.
Cryoport and MLC will partner to create synergistic value by leveraging each other’s global logistics networks. The partnership will provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. MLC has chosen to adopt Cryoport’s unique and proprietary temperature-controlled and traceability solutions to meet the increasing demand for cell and gene therapy supply chain solutions and to strengthen its logistics capabilities.
Jerrell Shelton, CEO of Cryoport, said: “MLC and Cryoport will encourage the use of each other’s network, infrastructure, knowledge and resources to enhance each other’s operational performance and to generate value for customers in Japan and overseas to meet demand from the increasing number of cell and gene therapies currently in development and expected to launch in coming years.”